Loading provider…
Loading provider…
Urology Physician in Los Angeles, CA
NPI: 1174546568Primary Employer
USC Care Medical Group, Inc
keckmedicine.org
HQ Phone
Get M.D. Siamak's Phone Numberphone_androidMobile
Get M.D. Siamak's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardOR State Medical License
2004
CA State Medical License
1997 - 2027
CA State Medical License

American Board of Urology
Urology
UC Davis School of Medicine
health.ucdavis.edu
Medical School
Until 1996
David Geffen School of Medicine at UCLA
medschool.ucla.edu
B.S. • Microbiology & Molecular Genetics
1988 - 1992
University of Southern California/LAC+USC Medical Center
Fellowship • Urologic Surgical Oncology
2002 - 2004
University of Southern California/Los Angeles General Medical Center (USC/LA General)
Residency • Urology
1996 - 2002
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99213Established patient office or other outpatient visit, typically 15 minutes | 231 | 280 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 217 | 309 |
| 3 | 52000Diagnostic examination of the bladder and bladder canal (urethra) using an endoscope | 166 | 265 |
| 4 | 99215Established patient office or other outpatient, visit typically 40 minutes | 57 | 76 |
| 5 | 99204New patient office or other outpatient visit, 45-59 minutes | 55 | 55 |
Adherence to National Comprehensive Cancer Network® Guidelines for Testicular Cancer.
Authors: Scott Eggener, Shane Pearce
Publication Date: 2016-09-20
Lead Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Non-Interventional Study
Lead Sponsor: ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Docetaxel, DRUG: Gemcitabine, DRUG: Bacillus Calmette Guerin
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Biomarker Analysis, PROCEDURE: Blood Product Collection